BMS-P5 |
Catalog No.GC48495 |
BMS-P5 est un inhibiteur spécifique et oralement actif de la peptidylarginine déiminase 4 (PAD4). BMS-P5 bloque la formation de NET induite par le MM et retarde la progression du MM dans un modèle de souris syngénique.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1550371-22-6
Sample solution is provided at 25 µL, 10mM.
BMS-P5 is an inhibitor of protein arginine deiminase 4 (PAD4; IC50 = 0.098 µM).1 It is selective for PAD4 over PAD1, -2, and -3 (IC50s = >10 µM for all). BMS-P5 (1 µM) inhibits citrullination of histone H3 and neutrophil extracellular trap (NET) formation induced by RPMI-8226- or MM.1S-conditioned medium in isolated human neutrophils. It delays disease onset and increases survival in a DP42 syngeneic mouse model of multiple myeloma when administered at a dose of 50 mg/kg.
1.Li, M., Lin, C., Deng, H., et al.A novel peptidylarginine deiminase 4 (PAD4) inhibitor BMS-P5 blocks formation of neutrophil extracellular traps and delays progression of multiple myelomaMol. Cancer Ther.19(7)1530-1538(2020)
Average Rating: 5
(Based on Reviews and 31 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *